Tirzepatide and semaglutide are both medications that target weight loss and blood sugar control, but they differ in their mechanisms of action and formulations
By week 12, cumulative weight loss of 56% of baseline body weight is common in clinical trials, though individual results vary
As body weight decreases, the cardiovascular system experiences reduced workload, and this often translates into lower blood pressure readings
After completing your program, you will have the tools, habits, and knowledge required to keep the weight off for good
2.5 Quality assessment and risk of bias In line with PRISMA guidelines, the assessment of methodological quality was conducted to evaluate the strength of evidence, recognising that methodological limitations may introduce bias
Will the medication supply ever run out